Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06429293 · ClinicalTrials.gov registry record · NA
Impact of Cognitive Behavioral Therapy on PTSD-CVD Link
A NA study of Post Traumatic Stress Disorder, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06429293: Recruiting NA study of Post Traumatic Stress Disorder, sponsored by Massachusetts General Hospital.
NCT06429293 is a NA study of Post Traumatic Stress Disorder that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06429293, a NA study of Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot randomized controlled trial to assess the impact of a first-line treatment for posttraumatic stress disorder (PTSD) (Cognitive Processing Therapy; CPT) versus waitlist control on mechanisms of cardiovascular disease (CVD) risk. Further, this study will test the hypothesis that CPT reduces CVD risk through its effects on inflammation and autonomic function and that these changes are driven by changes in stress-related neural activity (SNA)
Primary Outcome
Measured via FDG-PET imaging
Conditions Studied
Interventions
- BEHAVIORAL Cognitive processing therapy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
What NCT06429293 shows while recruiting
NCT06429293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 1 intervention - of which Cognitive processing therapy is the first listed.
NCT06429293 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06429293 about?
NCT06429293 is a clinical study titled "Impact of Cognitive Behavioral Therapy on PTSD-CVD Link". This is a pilot randomized controlled trial to assess the impact of a first-line treatment for posttraumatic stress disorder (PTSD) (Cognitive Processing Therapy; CPT) versus waitlist control on mechanisms of cardiovascular disease (CVD) risk. Further, this study will test the hypothesis that CPT re...
What is the current status of trial NCT06429293?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-07-01. Estimated completion is 2026-07-01.
What conditions does trial NCT06429293 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT06429293?
The interventions under investigation include: Cognitive processing therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06429293?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06429293 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06429293's enrollment target sits among peer trials
30 210th of 262 higher than 44 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Targeting the Default Mode Network: A TMS-fMRI Study
RECRUITING · NA
-
The Effects of Very Brief Exposure on PTSD in U.S. Combat Veterans
RECRUITING · NA
-
Fear and Avoidance in PTSD Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI